Compare ALEMBIC PHARMA with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs GLENMARK PHARMA - Comparison Results

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA GLENMARK PHARMA ALEMBIC PHARMA/
GLENMARK PHARMA
 
P/E (TTM) x 15.2 12.6 120.2% View Chart
P/BV x 3.5 1.8 193.5% View Chart
Dividend Yield % 1.1 0.5 203.6%  

Financials

 ALEMBIC PHARMA   GLENMARK PHARMA
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-19
GLENMARK PHARMA
Mar-19
ALEMBIC PHARMA/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs664712 93.3%   
Low Rs412484 85.3%   
Sales per share (Unadj.) Rs208.7349.6 59.7%  
Earnings per share (Unadj.) Rs31.032.8 94.6%  
Cash flow per share (Unadj.) Rs37.144.3 83.7%  
Dividends per share (Unadj.) Rs5.502.00 275.0%  
Dividend yield (eoy) %1.00.3 305.4%  
Book value per share (Unadj.) Rs144.2198.6 72.6%  
Shares outstanding (eoy) m188.52282.17 66.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.61.7 150.9%   
Avg P/E ratio x17.418.2 95.2%  
P/CF ratio (eoy) x14.513.5 107.6%  
Price / Book Value ratio x3.73.0 124.0%  
Dividend payout %17.76.1 290.8%   
Avg Mkt Cap Rs m101,461168,625 60.2%   
No. of employees `000NA12.0 0.0%   
Total wages/salary Rs m7,46720,561 36.3%   
Avg. sales/employee Rs ThNM8,196.0-  
Avg. wages/employee Rs ThNM1,708.1-  
Avg. net profit/employee Rs ThNM768.5-  
INCOME DATA
Net Sales Rs m39,34798,655 39.9%  
Other income Rs m942,081 4.5%   
Total revenues Rs m39,441100,736 39.2%   
Gross profit Rs m8,73615,858 55.1%  
Depreciation Rs m1,1523,259 35.4%   
Interest Rs m1843,346 5.5%   
Profit before tax Rs m7,49311,335 66.1%   
Minority Interest Rs m110-   
Prior Period Items Rs m-930-   
Extraordinary Inc (Exp) Rs m01,672 0.0%   
Tax Rs m1,5683,756 41.7%   
Profit after tax Rs m5,8449,250 63.2%  
Gross profit margin %22.216.1 138.1%  
Effective tax rate %20.933.1 63.1%   
Net profit margin %14.99.4 158.4%  
BALANCE SHEET DATA
Current assets Rs m19,57766,968 29.2%   
Current liabilities Rs m14,89640,211 37.0%   
Net working cap to sales %11.927.1 43.9%  
Current ratio x1.31.7 78.9%  
Inventory Days Days9083 107.7%  
Debtors Days Days4581 55.9%  
Net fixed assets Rs m27,09733,322 81.3%   
Share capital Rs m377282 133.6%   
"Free" reserves Rs m26,81155,770 48.1%   
Net worth Rs m27,18856,052 48.5%   
Long term debt Rs m4,99335,738 14.0%   
Total assets Rs m47,778132,888 36.0%  
Interest coverage x41.74.4 950.5%   
Debt to equity ratio x0.20.6 28.8%  
Sales to assets ratio x0.80.7 110.9%   
Return on assets %12.69.5 133.1%  
Return on equity %21.516.5 130.2%  
Return on capital %23.617.8 132.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m19,45362,998 30.9%   
Fx outflow Rs m6,06522,859 26.5%   
Net fx Rs m13,38840,140 33.4%   
CASH FLOW
From Operations Rs m8,12013,242 61.3%  
From Investments Rs m-7,556-6,990 108.1%  
From Financial Activity Rs m590-7,387 -8.0%  
Net Cashflow Rs m1,153-2,971 -38.8%  

Share Holding

Indian Promoters % 74.1 48.3 153.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 6.9 42.0%  
FIIs % 9.1 34.4 26.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 10.5 132.4%  
Shareholders   49,328 56,727 87.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   J.B.CHEMICALS  SUVEN LIFESCIENCES  CIPLA  ELDER PHARMA  VENUS REMEDIES  

Compare ALEMBIC PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 262 Points Lower; Oil & Gas and Banking Stocks Witness Selling(Closing)

Indian share markets witnessed negative trading activity throughout the day and ended lower. At the closing bell, the BSE Sensex stood lower by 262 points (down 0.7%).

Related Views on News

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 36.4% (Quarterly Result Update)

Aug 21, 2019 | Updated on Aug 21, 2019

For the quarter ended June 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 36.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.0% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 13, 2019 | Updated on Jun 13, 2019

Here's an analysis of the annual report of ALEMBIC PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Sep 16, 2019 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA - TTK HEALTHCARE COMPARISON

COMPARE ALEMBIC PHARMA WITH

MARKET STATS